Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)
Key claim: CALR allele burden monitoring may serve as a clinically relevant molecular marker for disease progression diagnosis and follow-up in patients with CALR-mutated myeloproliferative neoplasms.
Abstract
Prospective study to evaluate the relevance of CALR allele burden monitoring as a molecular marker of disease progression.
Why this matters
Allele burden monitoring has been a JAK2-centric tool in transplant decision-making, but roughly a quarter of MF patients are CALR-mutated and currently lack an analogous quantitative molecular marker for tracking disease trajectory. If CALRSUIVI validates CALR allele burden dynamics as a progression signal, it could feed directly into pre-transplant risk reassessment and bridging response monitoring for this subgroup, complementing MIPSS70-style mutation-based scoring with a longitudinal quantitative measure.